RecruitingNCT07119424

Multidisciplinary Dissection of Renal and Metabolic Effects of Glyfozines on Elderly Patients: From Molecular Aspects to Clinical Indications

Sponsor

Chiara Lanzani

Enrollment

300 participants

Start Date

Feb 14, 2025

Study Type

OBSERVATIONAL

Conditions

Elderly Patients (>65 Years)Heart Disease Diabetes (DM)Renal Diseases Internal Disease

Summary

The project aims to study the impact of SGLT2i therapy on clinical and biochemical aspects. in elderly. The project will combine different types of data, such as clinical and biological information, and will use advanced Bayesian statistical methods to understand the relationship between risk factors and patient outcomes following treatment with SGLT2 inhibitors.

Eligibility

Min Age: 65 Years

Inclusion Criteria6

Participant is willing and able to give informed consent for participation in the study;
Patients must be enrolled also in MED-Cli e MED-Mol studies by signing both the MED-Cli e MED-Mol informed consents.
The medical product is the standard of care for the patient and has been prescribed according to clinical practice and independent of the present study;
Age ≥65 years;
Participant has not yet started the prescribed SGLT2i therapy;
Participant has at least one clinical indication for SGLT2i use according to clinical practice guidelines.